Techstars Doubles Down on European Commitment With the Launch of Two New Accelerator Programs in Paris and Stockholm
14.9.2021 11:00:00 EEST | Business Wire | Press release
Techstars, the worldwide network that helps entrepreneurs succeed, announces the launch of two new accelerator programs in Paris and Stockholm. The launch showcases Techstars’ commitment to investing in startup talent in Europe, where it plans to invest in more than 100 startups in 2022 through its various accelerator programs in seven countries. Both programs will be fully funded by Techstars, following the recent July close of a new $150 million fund, intended to support more local entrepreneurs looking for global exposure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005314/en/
A Techstars Accelerator Office (Photo: Business Wire)
The Paris Techstars Accelerator and Stockholm Techstars Accelerator will each accept 12 startups per class, who will benefit from up to $120k in funding alongside evergreen access to Techstars’ vast network of mentors, investors, alumni and corporate partners. The Paris accelerator will operate two classes per year, while Stockholm will run once in 2022 and twice per year from 2023 onwards. Applications for these accelerators open today and will close on 1 December 2021, with the first classes of both programs due to commence on 21 March 2022.
Applications will be accepted from startups across all high-growth sectors, both B2B and B2C, and successful applicants will have a strong founding team who are using technology to tackle complex problems, with a clear and scalable product-market fit.
The Paris and Stockholm Techstars Accelerator programs follow the recent appointment of French-born CEO, Maëlle Gavet, in January 2021. An experienced French entrepreneur and former executive at Compass and Booking.com, Gavet’s experience scaling companies across Europe will assist Techstars on its mission to help more entrepreneurs in more places transform the world through access to capital and a global network.
Techstars currently operates 47 accelerators in 33 cities and 12 countries around the world, and while it previously operated a Paris-based accelerator in partnership with corporate partners, the Stockholm Techstars Accelerator marks its first venture into Sweden as it eyes expansion opportunities across Europe. Since 2009 and 2010, the company has been actively supporting thousands of entrepreneurs in Paris and Stockholm, respectively, by hosting more than 90 Techstars Startup Weekend programs in both cities, in close collaboration with local ecosystem leaders. Additionally in Europe, Techstars operates programs in London, Amsterdam, Berlin, Oslo and Turin.
Since its inception in 2006, Techstars has invested in 2,589 companies, which today have a combined market capital valuation of $220.1 billion. It counts 15 unicorns among its accelerator graduates, including DigitalOcean, Chainalysis, PillPack and SendGrid. Techstars invests in approximately 500 startups and deploys approximately $130M per year, making it one of the largest investors in high-growth early-stage companies by volume in the world.
Maëlle Gavet, CEO of Techstars, said: “We believe in the power of local ecosystems and that life-changing ideas can come from anywhere in the world - you don’t need to be in Silicon Valley to be a success. At Techstars, we meet the founders where they are and use our local networks to give them access to world-class capital and investing opportunities they wouldn’t otherwise have. Paris and Stockholm are two of Europe’s most rapidly growing yet underserved tech hubs, and we know there is a huge amount of talent there ready to be harnessed.”
Applications to apply to the Paris Techstars Accelerator and Stockholm Techstars Accelerator are open now.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,589 companies with a combined market cap of more than $220.1B. www.techstars.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005314/en/
Contact information
Ballou PR
Fiona Houston: +44 7935 105 338
Kelly Horn: +44 7767 649 727
Techstars
Jennifer Pakradooni: +1 305 772 3834
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom